CN104784199A - Glycan composition for activating immunity to treat pathogen infection - Google Patents
Glycan composition for activating immunity to treat pathogen infection Download PDFInfo
- Publication number
- CN104784199A CN104784199A CN201410024080.4A CN201410024080A CN104784199A CN 104784199 A CN104784199 A CN 104784199A CN 201410024080 A CN201410024080 A CN 201410024080A CN 104784199 A CN104784199 A CN 104784199A
- Authority
- CN
- China
- Prior art keywords
- acid
- polysaccharide
- calcium
- compositions
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to a composition prepared by connecting glycan with functional elements through fatty acid or a salt or derivative of the fatty acid. The composition can enhance the immunity of human bodies and animals to substantially improve the pathogen infection treatment function of glycan, and especially has a substantial treatment effect on virus diseases. The composition is of positive significance to reducing the dependence of the breeding industry on antibiotics, and plays a great role in the development of antivirus preparations.
Description
Technical field
The present invention relates to polysaccharide composition preparing the application in activate immunity resistant treatment human body and Animal diseases medicine, belonging to biological technical field.
Background technology
The development of modern poultry and aquaculture industry plays a very important role for China's economic development and environment sustainable development.But along with the raising of cultivation intensive degree, the density of the animal cultivation such as poultry and fish shrimp crab is large, adds a large amount of uses of hormone or antibiotic etc., animal growth rate is fast, and the ability of animal anti-stress significantly weakens, and immune resistance is low, be very easy to cause the popular of disease, cause animal mortality.
Stress under environment, the irritability of animal body feeding center reduces, neuroendocrine disorders, and the hormone secretion such as thyroxine, epinephrine is disorderly, degradation under human body immune function.Such as, pig cultivation aspect be mainly manifested in following several respects: 1) feed intake reduces, and grower pigs weightening finish is slowly.2) pig breeding dysfunction is planted.Sow hypo ovaria, miscarriage, conception rate decline, the increase of stillborn fetus number, lactation amount decline, piglet survival ratio reduction etc.; Breeding boar hyposexuality, semen quality decline, sperm quantity minimizing, vigor reduction, abnormal rate rising etc.3) disease such as the dermatitis nephrotic syndrome, baby pig diarrhoea, unknown high fever, chronic ileitis increases.4) meat quality reduces.5) virosis is popular.Then there is the poor growths such as shrimp Eriocheir sinensis, shelling difficulty, disease popularity, mortality in aquatic products.
Traditional method is mainly through adding the anti-stress ability of anti-stress additive as enhancing animals such as fat, synthesizing amino acid, electrolyte, mineral, vitamin and organic acids, or the resistance against diseases by using antibiotic and vaccine to strengthen animal, can play a role.But due to a large amount of uses of these products, not only bring the food-safety problems such as the residue of veterinary drug further received publicity, result also in the day by day serious resistance of pathogenic microorganism and produce, serious challenge is constituted to the development of aquaculture.
Virus is minimum pathogenic microorganism, is not have a cellularity, but has heredity, the microorganism of vital signs such as to copy, and its core is ribonucleic acid or DNA (deoxyribonucleic acid) (DNA).Virus is not only the important infectious disease infecting human body, and is the Important Infectious Diseases infecting poultry.In recent years more variation becomes the infectious disease of infecting both domestic animals and human as avian influenza viral disease etc.The disease caused by virus in health mainly contains infectious hepatitis, herpes, encephalitis, viral respiratory tract infection, influenza and herpetic keratitis and acquired immune deficiency syndrome (AIDS) etc.According to foreign statistics, the infectious disease of nearly 3/4 is caused by virus, 18 kinds are had to belong to Causative virus in 55 kinds of viruses that international virus taxis association (ICTV) in 1984 has been announced, different viral infection causes different illness, need different antiviral treatments, and virus variation speed is very fast, defines multiple type as influenza virus has made a variation, make to adopt vaccine prevention viral infection abnormal difficult.
The approach of current viral infection resisting mainly contains, and directly suppresses or kill virus, viral interference absorption, stops virus to penetrate cell, suppresses viral organism synthesis, suppress virus release or strengthen host anti-virus ability etc.Although current antiviral drugs is clinically more, but be mostly nucleoside derivate, its Main Function target spot is viral dna polymerase, compete with the form of enzyme reaction substrate analog and normal substrates, directly the activity of reduction or blocking dna polymerase, shows certain antiviral activity, but it has and easily produces drug resistance, antiviral narrow range, the shortcomings such as toxic and side effects is large, expensive.In recent years, the effect of some Chinese herbal medicine in antiviral property disease also result in the concern of people, but the stability of antiviral Chinese herbal medicine infectious disease is not then the bottleneck limiting its application.
In recent years, some experts and scholars start to be concerned about polysaccharose substance and are strengthening the effect in human body and animal immune resistance, the effect in the Immunoresistance improving animal body both at home and abroad.Domestic and international research finds, polysaccharide such as chitosan can increase the immune resistance of animal.But because the application of single component acts on instability in actual applications, the effect of polysaccharide is not given prominence to, human body or animal use after infection virosis, can not play the effect for the treatment of virus disease.
The polysaccharide that the degree of polymerization is determined by the present invention is connected a kind of compositions made with functional element using fatty acid cpds or derivatives thereof as molecular bridge, can greatly active cell immunologic function, thus improve human body and animal body immune resistance, make it have the effect of broad-spectrum disease resistance, especially compositions still can have the effect for the treatment of virosis after human body or animal are subject to viral infection.
Summary of the invention
By the fatty acid of one or more polysaccharide in following structure or the work of soap or derivatives thereof molecular bridge
and/or
In formula, X is H, C
1-C
31alkyl or alkenyl, 2-hydroxyethyl, 2-hydroxypropyl;
Y is H, C
1-G
4alkyl or alkenyl, metal or nonmetalloid or group;
Z is H, OH, C
1-C
4alkyl or alkenyl, metal or nonmetalloid or group;
The glycan pool thing that the enhancing immune resistance made treats human body and animal courses of infection is combined with lower to be connected in blending agent with one or more functional elements.The pH value of described compositions is 2.0-3.9.
The described polysaccharide selected is that the monosaccharide being 6 carbon atoms by 9-2500 base molecule formula is polymerized, and these polysaccharide can from plant, animal or microorganism, including, but not limited to: trehalose, starch, soluble starch, aminopolysaccharide, amino-oligosacchride, chitosan, glycosaminoglycans, chitosan, cellulose, hemicellulose, Cordyceps polysaccharide, astragalus polysaccharides, ginseng polysaccharide, Radix Notoginseng polysaccharide, dictyophora fungus polysaccharide, ganoderan, lentinan, zymosan etc.
The fatty acid cpds or derivatives thereof molecular bridge selected is saturated or undersaturated fatty acid from C2 to C28 or soap or derivant, including, but not limited to acetic acid, and diacetic acid, propanoic acid, butanoic acid, isopropylformic acid., valeric acid, isovaleric acid, caproic acid, isocaproic acid, certain herbaceous plants with big flowers acid, sad, Palmic acid, palmitic olefinic acid, stearic acid, linoleic acid, oleic acid, lauric acid, myristic acid, n-nonanoic acid, arachidonic acid etc., and the salt made of these fatty acids or derivant.
The blending agent selected is mixed by water and one or more compositions following: sulphuric acid, acetic acid, formic acid, acetic acid, diacetic acid, phosphoric acid, nitric acid, hydrochloric acid, phosphorous acid, sulfurous acid, boric acid, glacial acetic acid, butanoic acid, phthalic acid, p-phthalic acid, succinic acid, humic acids, salicylic acid, para-amino benzoic acid, ortho-aminobenzoic acid, benzoic acid, dimethyl sulfoxide, benzylamine, propylene glycol, cyclohexylamine etc.
The described functional element selected is for containing one or more potassium, sodium, calcium, magnesium, zinc, aluminum or selenium compound, including, but not limited to calcium chloride, sodium chloride, potassium chloride, zinc oxide, magnesium oxide, selenium oxide, calcium superphosphate, Sodium triphosphate, sodium bicarbonate, sodium polyphosphate, potassium dihydrogen phosphate, dipotassium hydrogen phosphate, sodium sulfate, aluminum sulfate, Selenium Sulphate, sulfurous acid selenium, magnesium sulfate, zinc sulfate, copper sulfate, zinc acetate, amino-acid zinc, potassium sulfate, dalcium biphosphate, dicalcium phosphate, calcium carbonate, amino acid calcium, amino-acid zinc, amino acid selenium, glucosan calcium, glucosan zinc, sodium carbonate, calcium bicarbonate, potassium bicarbonate, calcium sulfate, lime nitrate, calisanin, potassium carbonate etc.
The ratio joined by one or more polysaccharide above-mentioned in 2-5: 1 after mixing in blending agent adds molecular bridge, adds functional element after mix homogeneously, in temperature 5 DEG C to 95 DEG C and pH1.8 to pH4.9, be mixed and made into compositions.
The technical problem that the present invention solves utilizes fatty acid or derivatives thereof as molecular bridge, polysaccharide to be combined the compositions made with functional element, the effect that this compositions improves alone polysaccharide or simply mixed with fatty acid or derivatives thereof by polysaccharide, also the action effect of polysaccharide ester is extended, significantly enhance the immune resistance of human body or animal, in treatment human body and Animal diseases, there is remarkable result.
Detailed description of the invention
The present invention is further described according to following example, one skilled in the art will appreciate that following embodiment only plays the effect of explanation to the present invention.Without departing from the premise in the spirit of the present invention, any improvement the present invention done and substituting all in the scope of protection of the invention.
Embodiment one
Get chitosan 10g to join in 500 milliliter of 0.5 mole hydrochloride, add sad 5g, stir at 35 DEG C, add aluminum sulfate 15g respectively, glucosan calcium 2g, dipotassium hydrogen phosphate 20g, threonine zinc 10g stirs at 25 DEG C.PH value sulphuric acid is adjusted to 2.9, makes the glycan pool thing containing functional element.
Embodiment two
Adopt classical effect on hepatitics B virus in vitro medicaments sifting model HepG2.2.15 cell model, compositions administration HepG2.2.15 cell a couple of days of variable concentrations, get cell conditioned medium liquid, by measuring hepatitis B surface antigen (HBsAg), e antigen (HBeAg) and HBVDNA secretion judge effect of drugs.Mtt assay is adopted to measure the cytotoxicity of compositions in experimentation.Choose the verified effective antiviral drugs lamivudine (3TC) of clinical practice in contrast.
When HepG2.2.15 cell proliferation to a certain extent and antigen secretion stable after, carry out cell counting, obtained cell suspension is cultivated in 96 well culture plates, every hole 100 μ L, makes every porocyte concentration reach 2000, after cultivating 24h, absorb cell conditioned medium liquid, the compositions adding variable concentrations continues cultivation 6 days, and period changes a pastille culture medium, and collecting cell supernatant is stored in-70 DEG C of refrigerators for subsequent use.Repeat 3 times.
ELISA method is adopted to measure the content determination compositions of HBsAg and HBeAg in cell conditioned medium liquid to the suppression situation of two kinds of antigens.Get the HepG2.2.15 cell conditioned medium liquid of contrast medicine 3TC and the administration of compositions variable concentrations, according to the operation of test kit operation instruction, measure cell conditioned medium OD value, calculation composition is to the suppression ratio of HBsAg and HBeAg.
The toxicity of design team's compound to cell under variable concentrations 10,100,500 μ g/mL, the concentration of contrast medicine 3TC is set to normal concentration 100 μ g/mL, and toxic degree adopts MTT colorimetric method for determining.By the above-mentioned MTT serum-free medium 20 μ L that have collected the every hole of the culture plate after supernatant and added 5mg/mL, in incubator, cultivate 4h, careful reject supernatant, add 150 μ L dimethyl sulfoxide, vibration 10min, colorimetric determination OD value under 550nm wavelength.
Compositions to the inhibitory action of HepG2.2.15 emiocytosis HBsAg and HBeAg in table one and table two.Along with the increase of concentration, compositions increases the suppression ratio of hepatitis B surface antigen HBsAg and e antigen HBeAg, when composition concentration reaches 500 μ g/mL, 30.84% and 29.84% are respectively to the suppression ratio of HBsAg and HBeAg, the suppression ratio of control drug 3TC to HBsAg and HBeAg is respectively 29.12% and 31.59%, there was no significant difference (P > 0.05) between compositions and control drug.
Table one compositions is to the inhibitory action of HepG2.2.15 emiocytosis HBsAg
Table two compositions is to the inhibitory action of HepG2.2.15 emiocytosis HBeAg
The result display of MTT, when the concentration of compositions is less than or equal to 500 μ g/mL, cell survival rate > 95%.3TC positive control is the anti-hepatitis virus preferably concentration of being screened by many experiments, and data analysis only adopts 100 μ g/mL.3TC is in compositions relative analysis.The compositions of variable concentrations and the cytotoxic assay of 3TC the results are shown in Table three.Measurement result shows that compositions is very high to the safety of cell.
Table three compositions is to the cytotoxicity of HepG2.2.15
Embodiment three
Choosing have the pig 30 of viral infection symptoms: gradual become thin or growth retardation, anorexia, spirit depressed, be slow in action, palor, dyspnea fluffy and disorderly by hair, cough etc.Be divided into treatment group and matched group, two groups of affected pig ages, clinical manifestation and state of an illness weights are unanimous on the whole.Each 15 examples for the treatment of group matched group, treatment group joins in 500ml drinking water by 10ml compositions, and every pig is pressed and supplies 500ml/ day.Matched group isolated rearing, Routine Management.The mental status, the body temperature of pig, situation of searching for food is observed every day after process.Sick pig medication clinical symptom disappearance after 5 days, the normal person of body temperature, appetite, the mental status is judged to healing; Sick pig medication is appetite, mental status improvement after 5 days, and the normal person of body temperature is judged to improvement; Taking a turn for the better and curing all is judged to effectively; Sick pig medication after 10 days still lassitude, anorexia or death be judged to invalid.Result is as table four.
The effect of table four drinking technique compositions treatment virosis pig
Compositions joins the therapeutic effect of drinking water to viral pig and reaches 86.7%, and the sick pig of matched group has 8 death, does not still get well after 10 days for 7.Compositions has the therapeutic effect of highly significant.
Embodiment four
Choosing has the pig 20 of virus symptoms.Be divided into treatment group and matched group, two groups of affected pig ages, clinical manifestation and state of an illness weights are unanimous on the whole.Each 10 examples for the treatment of group matched group, treatment group joins mix homogeneously in 500g feedstuff by 15ml compositions.Matched group isolated rearing, Routine Management.The mental status, the body temperature of pig, situation of searching for food is observed every day after process.Sick pig medication clinical symptom disappearance after 5 days, the normal person of body temperature, appetite, the mental status is judged to healing; Sick pig medication is appetite, mental status improvement after 5 days, and the normal person of body temperature is judged to improvement; Taking a turn for the better and curing all is judged to effectively; Sick pig medication after 10 days still lassitude, anorexia or death be judged to invalid.
The effect of table five feedstuff method compositions treatment virosis pig
The therapeutic effect being added compositions by feedstuff reaches 70%, and the sick pig of matched group has 5 death, does not still get well after 10 days for 3.Compositions has the therapeutic effect of highly significant.
Embodiment five
Get Healthy female mice and be divided into 3 groups, 10/group, average every only heavy 20g.Get well-grown mouse bearing liver cancer H22 cell and be adjusted to 2 × 10 with normal saline
6the cell suspension of individual/ml concentration, is inoculated in right side of mice armpit by 0.2ml/ volume subcutaneous.Negative control group synchronously gives N.S. with tested group.Test component is high dose composition (150mg/Kg) and low dose group compound (75mg/Kg) two subgroups.By administration volume gastric infusion (ig) successive administration 10 days of 0.3ml/10g, administration terminates rear next day gets tumor and weighs and calculate tumour inhibiting rate.
The impact that table six compositions grows rat liver cancer H22
The compositions gastric infusion of various dose has certain inhibition to animal hepatocarcinoma.Relative to chemical anti-tumor drugs, the feature of this compositions does not affect animal appetite, and weight ratio negative control group increase about 10% when animal subject administration completes, shows that product of the present invention has good using value.
Claims (10)
1. the glycan pool thing of activate immunity resistant treatment courses of infection, is characterized in that: by one or more polysaccharide under the fatty acid of following structure or the effect of soap or derivatives thereof molecular bridge with a kind of or many
and/or
In formula, X is H, C
1-c
31alkyl or alkenyl, 2-hydroxyethyl, 2-hydroxypropyl;
Y is H, C
1-C
4alkyl or alkenyl, metal or nonmetalloid or group;
Z is H, OH, C
1-C
4alkyl or alkenyl, metal or nonmetalloid or group;
Plant functional element in blending agent, connect the glycan pool thing combining enhancing immune resistance treatment human body and the animal courses of infection made.
2. compositions according to claim 1, is characterized in that: described polysaccharide is that the monosaccharide being 6 carbon atoms by 9-2500 base molecule formula is polymerized, and these polysaccharide can from plant, animal or microorganism, including, but not limited to: trehalose, starch, soluble starch, aminopolysaccharide, amino-oligosacchride, chitosan, glycosaminoglycans, chitosan, cellulose, hemicellulose, Cordyceps polysaccharide, astragalus polysaccharides, ginseng polysaccharide, Radix Notoginseng polysaccharide, dictyophora fungus polysaccharide, ganoderan, lentinan, zymosan etc.
3. compositions according to claim 1, is characterized in that: described fatty acid cpds or derivatives thereof molecular bridge is saturated or undersaturated fatty acid from C2 to C28 or soap or derivant, including, but not limited to acetic acid, diacetic acid, propanoic acid, butanoic acid, isopropylformic acid., valeric acid, isovaleric acid, caproic acid, isocaproic acid, certain herbaceous plants with big flowers acid, sad, Palmic acid, palmitic olefinic acid, stearic acid, linoleic acid, oleic acid, lauric acid, myristic acid, n-nonanoic acid, arachidonic acid etc., and the salt made of these fatty acids or derivant.
4. compositions according to claim 1, is characterized in that: described in selected polysaccharide and claim 1, the mixing ratio of structural molecule bridge is 2-5: 1.
5. compositions according to claim 1, it is characterized in that: one or more polysaccharide above-mentioned are joined in blending agent and add molecular bridge after mixing, add functional element after mix homogeneously, in temperature 5 DEG C to 95 DEG C and pH1.8 to pH4.9, be mixed and made into compositions.
6. immune resistance according to claim 1, the feature of described immune resistance is including, but not limited to promoting that human body or animal white blood cell are as the increase of lymphocyte and macrophage equal size.
7. human body diseases according to claim 1, including, but not limited to the influenza virus that the disease affecting health causes as virus, hepatitis B virus, HIV (human immunodeficiency virus), herpesvirus and bird flu virus etc., fungus-caused tinea unguium and tinea etc., bacterial skin ulcer, dysentery etc., and the tumor disease etc. that cell carcinogenesis causes.
8. Animal diseases according to claim 1, including, but not limited to the virus of the Aquatic product such as poultry and fish shrimp crab of causing harm and bacterial disease as bird flu, swine flue, Eriocheir sinensis ring pawl is sick, fish molds and streptococcicosis etc.
9. according to claim 5, it is characterized in that: described blending agent is mixed by water and one or more compositions following: sulphuric acid, acetic acid, formic acid, acetic acid, diacetic acid, phosphoric acid, nitric acid, hydrochloric acid, phosphorous acid, sulfurous acid, boric acid, glacial acetic acid, butanoic acid, phthalic acid, p-phthalic acid, succinic acid, humic acids, salicylic acid, para-amino benzoic acid, ortho-aminobenzoic acid, benzoic acid, dimethyl sulfoxide, benzylamine, propylene glycol, cyclohexylamine etc.
10. according to claim 5, it is characterized in that described functional element is for containing one or more potassium, sodium, calcium, magnesium, zinc, aluminum or selenium compound, including, but not limited to calcium chloride, sodium chloride, potassium chloride, zinc oxide, magnesium oxide, selenium oxide, calcium superphosphate, Sodium triphosphate, sodium bicarbonate, sodium polyphosphate, potassium dihydrogen phosphate, dipotassium hydrogen phosphate, sodium sulfate, aluminum sulfate, Selenium Sulphate, sulfurous acid selenium, magnesium sulfate, zinc sulfate, copper sulfate, zinc acetate, amino-acid zinc, potassium sulfate, dalcium biphosphate, dicalcium phosphate, calcium carbonate, amino acid calcium, amino-acid zinc, amino acid selenium, glucosan calcium, glucosan zinc, sodium carbonate, calcium bicarbonate, potassium bicarbonate, calcium sulfate, lime nitrate, calisanin, potassium carbonate etc.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410024080.4A CN104784199A (en) | 2014-01-20 | 2014-01-20 | Glycan composition for activating immunity to treat pathogen infection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410024080.4A CN104784199A (en) | 2014-01-20 | 2014-01-20 | Glycan composition for activating immunity to treat pathogen infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104784199A true CN104784199A (en) | 2015-07-22 |
Family
ID=53549702
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410024080.4A Pending CN104784199A (en) | 2014-01-20 | 2014-01-20 | Glycan composition for activating immunity to treat pathogen infection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104784199A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106509369A (en) * | 2015-09-11 | 2017-03-22 | 黄永 | New polysaccharide-ester biological material |
| WO2017118389A1 (en) * | 2016-01-04 | 2017-07-13 | 黄永 | Glycosaminoglycan ester and application thereof |
| CN106973936A (en) * | 2016-01-15 | 2017-07-25 | 黄永 | A kind of biological material of plant pest management |
| WO2018078532A1 (en) * | 2016-10-24 | 2018-05-03 | Agro Innovation International (A.I.I.) | Methods of rapidly preventing the spread of avian influenza virus in poultry flocks |
| CN109793753A (en) * | 2017-11-17 | 2019-05-24 | 成都澳立生态科技发展有限公司 | A kind of Derma-Guard of antibiotic skin-care |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101637156A (en) * | 2008-07-30 | 2010-02-03 | 黄永 | Composite of fatty acids and derivatives thereof |
-
2014
- 2014-01-20 CN CN201410024080.4A patent/CN104784199A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101637156A (en) * | 2008-07-30 | 2010-02-03 | 黄永 | Composite of fatty acids and derivatives thereof |
Non-Patent Citations (4)
| Title |
|---|
| 刘祝英: "复合多糖对断奶仔猪生产性能和免疫功能影响的研究", 《中国优秀硕士学位论文全文数据库 农业科技辑》 * |
| 肖定福: "壳聚糖对仔猪生长、肠道屏障和免疫的影响极其机理研究", 《中国博士学位论文全文数据库 农业科技辑》 * |
| 钮海华: "丁酸钠对断奶仔猪生长、免疫及肠道功能的影响极其机理研究", 《中国优秀硕士学位论文全文数据库 农业科技辑》 * |
| 陈银基等: "饱和脂肪酸分类与生理功能", 《中国油脂》 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106509369A (en) * | 2015-09-11 | 2017-03-22 | 黄永 | New polysaccharide-ester biological material |
| WO2017118389A1 (en) * | 2016-01-04 | 2017-07-13 | 黄永 | Glycosaminoglycan ester and application thereof |
| US10889608B2 (en) | 2016-01-04 | 2021-01-12 | Chengdu Auli Ecological Technology Development Co., Ltd. | Ester of aminoglycan and uses thereof |
| CN106973936A (en) * | 2016-01-15 | 2017-07-25 | 黄永 | A kind of biological material of plant pest management |
| WO2018078532A1 (en) * | 2016-10-24 | 2018-05-03 | Agro Innovation International (A.I.I.) | Methods of rapidly preventing the spread of avian influenza virus in poultry flocks |
| US10455833B2 (en) | 2016-10-24 | 2019-10-29 | Agro Innovation International (A.I.I.) | Methods of rapidly preventing the spread of avian influenza virus in poultry flocks |
| CN109793753A (en) * | 2017-11-17 | 2019-05-24 | 成都澳立生态科技发展有限公司 | A kind of Derma-Guard of antibiotic skin-care |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104784199A (en) | Glycan composition for activating immunity to treat pathogen infection | |
| CN104510729A (en) | Animal immune resistance-activating composition of fatty acid and derivatives thereof | |
| CN104012807A (en) | Antiviral compound vitamin premix feed preparation for livestock as well as preparation method and application of preparation | |
| CN101596246B (en) | Smoked plum extractive and wild jujube seed extractive compound preparation as well as preparation method and application thereof | |
| CN104095154B (en) | A kind of Cynoglossus semilaevis special immune reinforcing agent | |
| CN104083427A (en) | Compound astragalus polysaccharide particle for preventing and treating avian influenza | |
| CN105287790A (en) | Paederia scandens extract and applications thereof | |
| CN105192266A (en) | Whitebait aquatic product aquaculture feed | |
| CN104825459B (en) | A kind of glycyrrhetinic acid composition and its application | |
| CN103006820A (en) | Chinese medicinal composition with functions of clearing heat and drying dampness and preparation method thereof | |
| CN102550831B (en) | Cinnamic acid improves the application in the product of growth of animals or poultry performance in preparation | |
| AU2017205019B2 (en) | Glycosaminoglycan ester and application thereof | |
| CN102845594B (en) | Low-cholesterol animal health product | |
| CN106509369A (en) | New polysaccharide-ester biological material | |
| CN101757018A (en) | Polyinosinic powder for livestock and preparation method thereof | |
| CN105724826B (en) | A kind of prawn feed additive and its application | |
| CN106939054A (en) | A kind of aminoglycan ester | |
| CN106265736A (en) | A kind of compound Radix Astragali polysaccharide injection preparation method and application | |
| CN106036234A (en) | Shellfish immunoenhancer and preparation method and application thereof | |
| CN106974936A (en) | A kind of composition for improving broiler chicken coccidial vaccine immune effect and preparation method thereof | |
| CN101007049A (en) | Application of nitric oxide donor and Chinese herbal preparation on nonspecific immune function of prawns | |
| CN105126081A (en) | Chinese and Western medicine composition for chicken feeding and preparation method of composition | |
| Qiao et al. | Using Astragalus polysaccharide herbal supplement to improve disease resistance in poultry | |
| CN104171498A (en) | Green feed additive capable of treating runt pig and using method thereof | |
| CN109966289A (en) | Application of the dephnetin in anti-chicken coccidiasis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150722 |
|
| RJ01 | Rejection of invention patent application after publication |